A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

PURPOSE: The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC). METHODS: This randomized, phase III, open-label, multicenter trial enrolled first-line MBC patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Harbeck, Nadia, Saupe, Steffen, Jäger, Elke, Schmidt, Marcus, Kreienberg, Rolf, Müller, Lothar, Otremba, Burkhard Joerg, Waldenmaier, Dirk, Dorn, Julia, Warm, Mathias, Scholz, Michael, Untch, Michael, de Wit, Maike, Barinoff, Jana, Lück, Hans-Joachim, Harter, Philipp, Augustin, Doris, Harnett, Paul, Beckmann, Matthias W., Al-Batran, Salah-Eddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222915/
https://www.ncbi.nlm.nih.gov/pubmed/27798749
http://dx.doi.org/10.1007/s10549-016-4033-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222915/
https://www.ncbi.nlm.nih.gov/pubmed/27798749
http://dx.doi.org/10.1007/s10549-016-4033-3

Ejemplares similares